More than 80% of an administered dose of fluorouracil (FU) is eliminated by catabolism through dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme of pyrimidines (Diasio and Harris, 1989) . Tuchman and colleagues (1985) were the first to describe a patient with severe FU toxicity associated with a pyrimidine metabolism disorder. On the basis of another case report, Diasio et al (1988) conducted a familial study, the conclusions of which suggested an autosomal recessive pattern of inheritance for DPD deficiency. Since then, similar pharmacogenetic syndromes have been reported by the same group (Harris et al, 1991; Lu et al, 1993) , others (Houyau et al, 1993) and ourselves (Fleming et al, 1993) . We recently performed a review analysis on previously published cases of DPD deficiency associated with FU toxicity. It appeared that a complete absence of DPD activity is extremely rare and even partial enzyme activity might result in more or less severe FU toxicity . In addition, the fact that among 15 cumulated cases (most with digestive cancer) 13 (87%) were women was very striking and suggestive of a sex-linked deficiency in DPD activity. We report on the clinical and pharmacological results from 19 cancer patients with more or less intense FU-related toxicity, who were phenotyped in our centre as carrying a DPD deficiency diagnosed in peripheral blood mononuclear cells. Different features were analysed including sex ratio, the toxicity profile, and a possible link between the intensity of DPD deficiency and the severity of FU toxicity.
described (Fleming et al, 1993) . All the lymphocyte pellets were brought to our centre, where they were kept at Ð80°C, and DPD determination was performed within 2 weeks. DPD activity was determined as previously described (Fleming et al, 1993) . Briefly, the assay involved incubating lymphocyte extract (cytosol) with [ 14 C]FU, followed by high-performance liquid chromatography (HPLC) separation and quantification of [ 14 C]FUH 2 . Enzyme activity was expressed as fmol of FUH 2 formed per minute and per milligram of protein. The sensibility limit was 10 pmol min Ð1 mg Ð1 protein. The interassay reproducibility (aliquots of a pooled lymphocyte suspension) gave a coefficient of variation of 12%.
Statistics
Comparisons of frequencies were carried out by chi-squared test. Group comparisons were carried out by the MannÐWhitney test. Statistics were drawn up on SPSS software (Chicago, IL, USA). Table 1 summarizes the clinical, pharmacological and biological data concerning the 19 study patients with unanticipated FUrelated toxicity and significant DPD deficiency (lymphocytic DPD activity below 150 pmol min Ð1 mg Ð1 protein). Most FU chemotherapy protocols included FU modulation by folinic acid (12 out of 19, 63%). In four cases, patients had previously received a FU-based chemotherapy (more than 1 year before the present treatment). In two of them, patients 14 and 15, it was possible to retrieve an indication of FU-related toxicity (mild neurotoxicity for patient 14 and haematological toxicity for patient 15). There was a marked majority of women in this group of DPD deficient patients (15 out of 19, 79%). This population of women was significantly higher (P = 0.014) than that found in the remaining 34 patients (15 women out of 34, 44%), whose DPD was higher than 150 pmol min Ð1 mg Ð1 protein. Toxicities were often severe, leading to patient death in two cases (both women). The toxicity profile was typically related to FU in most cases (mucositis, neutropenia). The toxicity score was significantly higher in patients with markedly low DPD (below 100 pmol min Ð1 mg Ð1 protein) compared with patients with moderate DPD deficiency (below 150 and above or equal to 100 pmol min Ð1 mg Ð1 protein); the mean values of the toxicity score were 13.2 ± 5.9 (n = 11) and 6.8 ± 3.7 (n = 8) respectively (P = 0.008). There was a high proportion of neurotoxic syndromes (7 out of 19, 37%). The two deceased patients both had neurotoxicity. In contrast, the occurrence of cardiac toxicity was relatively rare (1 out of 19, 5%).
RESULTS

DISCUSSION
The present study provides clinical, pharmacological and biological data concerning 19 new cases of FU toxicity in relation to DPD deficiency. The group of patients analysed in the study represents more than the total number of isolated case reports published so far in the literature. The notion of DPD deficiency is hard to delineate precisely because it has been dependent upon the determination of lymphocytic DPD activity performed by different laboratories and, thus, included some degree of unavoidable analytical variability. The present prospective investigation performed in a single site had the advantage of avoiding this predictable interinstitution variability in DPD determination. After the analysis of lymphocyte samples taken from 53 patients who had developed an unexpected, more or less severe, FU-related toxicity, 19 (36%) revealed a relative DPD deficiency (below 150 pmol min Ð1 mg Ð1 protein, i.e. less than 70% of the mean population value; Etienne et al, 1994) . Similarly, Lu et al (1993) reported that in 25 cancer patients who had experienced moderate to severe FU-related toxicity, nine (36%) were found to have demonstrated a more or less marked DPD deficiency at lymphocyte level. It is clear that causes other than DPD deficiency can predispose to FU toxicity; these causes may include impaired liver function (Floyd et al, 1982) and altered nutritional status (Stenram, 1993) . It was not within the scope of the present study to investigate thoroughly the diverse origins of the FU-attributed toxic manifestations after FU-based chemotherapy in the whole group of patients.
One of the main findings which emerged from the exploration of the study patients is that the great majority of cases are women (79%). This observation cannot be explained by a sex-related tumour profile because most cases were digestive tract cancers. The proportion of women in the study group was significantly higher than in the remaining 34 patients from the whole group (15 women out of 34, i.e. 44%), whose DPD activity was not altered. This observation confirms the conclusions of earlier analyses in previously published case reports in which it was shown that women constituted 87% of DPD-deficient patients with FUrelated toxicity . We recently performed a prospective study on a large group of 185 unselected cancer patients and showed that lymphocytic DPD activity was, on average, 15% lower in women than in men. Interestingly, this 15% difference in DPD activity was of the order of magnitude as that observed for FU clearance between men and women . In contrast, in a population study by Lu et al (1993) , DPD activity was not influenced by sex. It must be stressed that the DPD gene is not carried by a sexual chromosome, but by chromosome 1 (Yokota et al, 1994) . Thus, the cause of the high frequency of women in DPD deficient patients is rather difficult to explain. The present data show that female patients are prone to carry a DPD-deficiency syndrome and should be given priority in systematic investigations of DPD activity before FUbased chemotherapy. This approach does not preclude careful consideration of the costÐbenefit ratio.
Neurotoxicity is rarely reported among the undesirable sideeffects of FU chemotherapy (Langer et al, 1996) . Takimoto and colleagues (1996) recently reported on a patient with DPD deficiency who developed severe neurotoxicity after 5FU-based chemotherapy. The present study clearly indicates that neurotoxicity plays a significant part in the toxicity profile exhibited by DPD-deficient patients after FU treatment. Neurotoxicity was predominant when DPD deficiency was marked: among the 11 patients with lymphocytic DPD below 100 fmol min Ð1 mg Ð1 protein, seven (including two toxic deaths) developed more or less severe toxicity. The aetiology of FU-related neurotoxicity is still poorly understood. In agreement with a previous report (Diasio et al, 1988) , it is suggested that neurotoxicity could be attributable to marked and prolonged exposure to FU in the CSF, secondary to plasma FU overexposure due to impaired drug clearance related to the DPD deficiency.
In contrast to neurotoxicity, patients with DPD deficiency did not present a particularly high incidence of cardiotoxicity because only one case (5%) was observed in the present study. The mechanisms of FU cardiotoxicity are unknown, but it is probable that this form of toxicity cannot be accounted for by FU pharmacokinetic abnormalities with drug overexposure due to DPD deficiency. This view strengthens previous findings by our group in which FU pharmacokinetic-monitored patients who developed FU-related cardiotoxicity did not present abnormal FU plasma concentrations (Thyss et al, 1988) . Another aspect of the present study is the fact that none of the reported cases had a complete DPD deficiency, even considering the two female patients who died from severe DPD toxicity. Patients with moderate DPD deficiency (between 100 and 150 fmol min Ð1 mg Ð1 protein) were predisposed to more or less severe FU-related toxicity. The severity of the toxicity was shown, however, to match the intensity of the DPD deficiency. This can be explained by a more or less marked overexposure to FU linked to the intensity of DPD deficiency because a significant relationship between lymphocytic DPD activity and FU clearance has been previously reported (Fleming, 1992) .
A molecular basis for DPD deficiency was recently suggested (Wei et al, 1996) . The authors found that a G to A mutation within the 5′ splicing site appeared to cause exon skipping, leading to an inactive DPYD allele. The physical map of the DPD gene was published recently (Johnson et al, 1997) . The classical assay for DPD activity determinations, as used in the present paper, is labour intensive and is not to be applied on a large scale. The recent basic findings concerning DPD should permit the development of rapid assays to detect mutations in the DPD gene. But it is not certain that genotyping will constitute a better solution than the current phenotyping approach, as different subjects genotyped as heterozygous for the 5′ splicing mutation may exhibit highly variable lymphocytic DPD activity among themselves (Wei et al, 1996) . Further studies need to be conducted with both genotyping and phenotyping to assess DPD deficiency and the risk of FUrelated toxicity.
